Once-daily hydrocortisone for adults with congenital adrenal hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether a once-daily hydrocortisone tablet works as well as standard steroid treatment for adults with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. It aims to improve how safely and conveniently hormone replacement is taken each day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old and can give informed consent
- You have congenital adrenal hyperplasia caused by 21-hydroxylase deficiency and adrenal insufficiency has been diagnosed
- Your current steroid (glucocorticoid) treatment has been stable, and you’re willing to switch based on the study’s random assignment
- You do not have serious problems affecting the brain, lungs, liver/bile, pancreas, kidneys, or severe long-term diarrhea
- You do not have alcohol/drug abuse, significant uncontrolled mental illness, or past known allergy to this dual-release hydrocortisone
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
This study checks hormone levels in saliva and blood using a precise test to better understand how the body balances steroids in people with congenital adrenal hyperplasia, a condition that affects hormone production.
This study follows adults with a genetic condition called congenital adrenal hyperplasia (CAH) who are switching to a new form of the steroid medication hydrocortisone. Researchers will track how well this modified-release version—which releases medication slowly over time—works for managing their condition in real-world practice.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.